Kolinpharma portfolio

The Enterprise has achieved 2 new EU patents with validity in Germany, France, and Italy, and 1 USA patent to confirm the efficacy and validity of the activity of R&D.

Milesax, which has achieved the concession of European patent and validity in Germany, France, and Italy, it is a food supplement formulated for well-being of the muscle.

Ivuxur, which has achieved the concession of European patent and validity in Germany, France, and Italy, it is a food supplement formulated for well-being of the urinary tract.

Almetax, which has achieved the concession of USA patent, it is a food supplement formulated thinking of the well-being of women in the period of menopause.

Rita Paola Petrelli, President of Kolinpharma, has commented: “We are proud to communicate that we have achieved new international patents, which allowed us to give major value of our products and the productive operation of the internal department of R&D.
...

KOLINPHARMA® has achieved the first patent for Doltendix®, the product was launched in June 2021, and actually, the number of patents has risen to 45 patents.

The department of R&D has developed Doltendix®, it is a food supplement formulated for the well–being of the tendons, based on bioactive peptides from collagen, astaxanthin, trans-resveratrol, and vitamin C.

Rita Paola Petrelli, President of Kolinpharma has commented: “After less one year from the launch of Doltendix®, we are proud to proclaim the concession of the patent in Italy, the result of the hard-working and profitable of the R&D.

We are aware of the value of our formulations, we are interested in requesting the demand of other patents foreign, according to our strategic line and we continue to invest in innovation of our product. 
 

KOLINPHARMA® signs an important three-year agreement with the multinational ASTAREAL® AB for distribution of products in Mainland China, Hong Kong, Macau, and Taiwan.

 The agreement, based on the Cross Boarder Ecommerce Law which entered into force in 2019, also provides that Kolinpharma® and AstaReal® undertake to make all the investments necessary for the setup of the e-commerce platforms and social media according to a digital marketing plan and a long-term strategy defined between the management of Kolinpharma® and the local skills of the headquarters team of Shangai by AstaReal®.

Rita Paola Petrelli, President of KOLINPHARMA®, commented: “We are proud to have sealed this very important partnership with the Swedish multinational, crucial for Kolinpharma's internationalization process. This agreement will allow us to initiate significant commercial development in a market with great potential such as the Asian one, that in China was worth 114.4 bi...

Even this year the company is one of 500 Italian enterprises that were distinguished for the major growth of turnover in the period of observation between 2018 and 2021 marking a CAGR of 15.93% turnover.

The study was born with the collaboration between “Il sole 24 Ore e Statista”, and analysed 8000 companies with a turnover superior of 100,000 Euro in 2018 and 1.5 million in 2021, which distinguished for high tax of growth about turnover, in terms of CAGR, achieved mainly at the organic level.

The ranking can be found online.
 

XINPROX®, studied and developed for the well–being of the prostate, is a food supplement that includes in the formulation raw materials of high quality, technologically advanced, and supported by scientific studies, such as pollen extract, quercetin, alpha lipoic acid, and L-tryptophan.

Now, Kolinpharma has 46 patents in total, 7 in Italy, 6 in USA, 1 in Israel, and 32 in the principal States of UE.

Rita Paola Petrelli, president of Kolinpharma has commented: “We are proud to announce that we have achieved the first patent for Xinprox® which testifies the validity of the formulations and the work of the R&D department and of the all company. […] The research is one of our elements of strengths and for this reason, we want to continue and invest and value our product to offer to costumer–patient scientifically validated solutions, patent is synonymous with synergy, uniqueness, and innovation".

 

 
 

Thanks to the active components such as dry extract of green tea, titrated in Epigallocatechingallate, saffron, trans-resveratrol (Veri-te®), citicoline (Cognizin®), zinc and other specific micronutrients, Declinex ® has the object to promote the well – being of the mind, it improves the mood and it has a targeted antioxidant action.